The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | The efficacy of plerixafor in the treatment of CLL
Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, shares some updates on the use of plerixafor, a CXCR4 antagonist, in the treatment of chronic lymphocytic leukemia (CLL). Dr Efremov first highlights the role of this drug in hematopoietic stem cell transplantation (HSCT), and then discusses the results from a recent Phase I trial which investigated the efficacy of plerixafor plus rituximab in the treatment of CLL. Following this, Dr Efremov discusses the role of inhibitors and monoclonal antibodies that target the colony-stimulating factor 1 receptor (CSF1R) in the treatment of cancers. To conclude, Dr Efremov discusses the use of anti-BAFF receptor monoclonal antibodies in combination with venetoclax, rituximab and ibrutinib, which are currently being investigated for the treatment of CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
